SENORES

Senores Pharmaceuticals Share Price

 

 

Invest in Senores Pharmaceuticals with 3.01X leverage

Invest with MTF

Performance

  • Low
  • ₹746
  • High
  • ₹783
  • 52 Week Low
  • ₹435
  • 52 Week High
  • ₹832
  • Open Price₹778
  • Previous Close₹777
  • Volume184,557

Investment Returns

  • Over 1 Month -8.54%
  • Over 3 Month + 4.66%
  • Over 6 Month + 41.24%
  • Over 1 Year + 92.49%

Smart Investing Starts Here Start SIP with Senores Pharmaceuticals for Steady Growth!

Invest Now

Senores Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 39.8
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 3,466
  • P/B Ratio
  • Average True Range
  • 28.1
  • EPS
  • 18.92
  • Dividend Yield
  • 0
  • MACD Signal
  • 9.54
  • RSI
  • 43
  • MFI
  • 47.18

Senores Pharmaceuticals Financials

Senores Pharmaceuticals Technicals

EMA & SMA

Current Price
₹752.65
-24.1 (-3.1%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹783.95
  • 50 Day
  • ₹762.12
  • 100 Day
  • ₹720.72
  • 200 Day
  • ₹647.22

Resistance and Support

760.65 Pivot Speed
  • R3 811.40
  • R2 797.15
  • R1 774.90
  • S1 738.40
  • S2 724.15
  • S3 701.90

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Senores Pharmaceuticals develops and manufactures niche, complex, and specialty pharmaceutical products adhering to international quality standards. With a global focus, the company is committed to innovation, affordable healthcare, and meeting the evolving demands of the healthcare industry.

Senores Pharmaceuticals Ltd has an operating revenue of Rs. 516.98 Cr. on a trailing 12-month basis. An annual revenue growth of 92% is outstanding, Pre-tax margin of 18% is great, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 22% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 95 which is a GREAT score indicating consistency in earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Senores Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-07-23 Quarterly Results & Others To consider other business matters.
2025-05-15 Audited Results
2025-01-23 Quarterly Results & Others To consider other business matters.

Senores Pharmaceuticals F&O

Senores Pharmaceuticals Shareholding Pattern

45.8%
3.54%
2.94%
4.28%
0.01%
31.09%
12.34%

About Senores Pharmaceuticals

  • NSE Symbol
  • SENORES
  • BSE Symbol
  • 544319
  • Managing Director
  • Mr. Swapnil Jatinbhai Shah
  • ISIN
  • INE0RB801010

Similar Stocks to Senores Pharmaceuticals

Senores Pharmaceuticals FAQs

Senores Pharmaceuticals share price is ₹752 As on 09 December, 2025 | 03:53

The Market Cap of Senores Pharmaceuticals is ₹3466.2 Cr As on 09 December, 2025 | 03:53

The P/E ratio of Senores Pharmaceuticals is 39.8 As on 09 December, 2025 | 03:53

The PB ratio of Senores Pharmaceuticals is 4.4 As on 09 December, 2025 | 03:53

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23